NASDAQ: TRMLTourmaline Bio Inc Stock
$15.68-0.32 (-2%)
Updated Apr 26, 2024
TRML Price
$15.68
Fair Value Price
N/A
Market Cap
$402.14M
52 Week Low
$9.18
52 Week High
$48.31
P/E
-1.77x
P/B
1.96x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$42.12M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
-$28M
Beta
1.4
Next Earnings
Jun 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TRML Overview
Talaris Therapeutics Incorporated is a late-clinical stage cell therapy company in the U.S. The company is developing a allogeneic, hematopoietic stem cell transplantation method which, if it succeeds, will transform the standard of care for solid organ transplantation and severe autoimmune diseases, as well as for severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, in a Phase II trial for living donor kidney transplant patients. Talaris was founded in 1988 and is headquartered in Louisville, KY.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TRML scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TRML is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TRML is good value based on its book value relative to its share price (1.96x), compared to the US Biotechnology industry average (5.85x)
P/B vs Industry Valuation
TRML is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TRML due diligence checks available for Premium users.
Be the first to know about important TRML news, forecast changes, insider trades & much more!
TRML News
Valuation
TRML price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.77x
Industry
14.88x
Market
41.14x
TRML price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.96x
Industry
5.85x
TRML is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TRML's financial health
Profit margin
Revenue
$0.0
Net Income
$2.1M
Profit Margin
0%
TRML's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$210.3M
Liabilities
$5.3M
Debt to equity
0.03
TRML's short-term assets ($208.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRML's short-term assets ($208.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRML's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$11.0M
Investing
-$88.4M
Financing
$156.5M
TRML's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TRML vs Biotech Stocks
Tourmaline Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.